Investor Presentaiton

Investor presentation Full year 2018 Slide 99 Strong growth in the long-acting haemophilia B market and RefixiaⓇ/RebinynⓇ has been launched in twelve countries Reported recombinant FIX sales RefixiaⓇ/RebinynⓇ launched in twelve countries Sales (USD million) 1,400 1,200 1,000 800 600 400 200 0 2011 Benefix® AlprolixⓇ CAGR: 10.1%¹ IdelvionⓇ 2017 • Launched in the first EU countries in 2017 . Launched in the USA in February 2018 • Approved in Japan in July 2018 • RefixiaⓇ/RebinynⓇ offers a unique clinical profile that brings factor levels into the non-haemophilia range for adults and adolescents • Dialogue ongoing with the FDA and the EMA to establish path forward to obtain routine prophylaxis indication in the USA and complete paediatric indication in Europe to include children younger than 12 years old 1 CAGR for 6-year period FIX: Coagulation factor IX Source: Company reports (does not include RixubisⓇ as sales are not reported separately) changing diabetes® FDA: the US Food and Drug Administration; EMA: European Medicines Agency rFIX: Recombinant coagulation factor IX novo nordisk

View entire presentation